Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening

Journal of Clinical Virology

Volumn 58, Issue 1, 2013, Pages 155-160

  Darlin, Lotten ^a   Borgfeldt, Christer ^a   Forslund, Ola ^a   Hénic, Emir ^a   Hortlund, Maria ^a,b   Dillner, Joakim ^b   Kannisto, Päivi ^a,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Cytology; HPV testing; Non attendance; Screening; Self collected vaginal smear; Vaginal smear

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HPV TEST; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT DEPARTMENT; PAPILLOMAVIRUS INFECTION; PATIENT ATTITUDE; PELVIC EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SELF EVALUATION; SWEDEN; VAGINA SMEAR; WORK EXPERIENCE;

EID: 84881556923     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.06.029     Document Type: Article

References (39)

1. Ferlay et al., Globocan on IARC 2004.
2. Arbyn M., Rebolj M., De Kok I.M., Fender M., Becker N., O'Reilly M., et al. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer 2009, 45:2671-2678.
3. Andrae B., Kemetli L., Sparén P., Silfverdal L., Strander B., Ryd W., et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008, 100:622-629.
4. Stenvall H., Wikstrom I., Backlund I., Wilander E. Accuracy of HPV testing of vaginal smear obtained with a novel self-sampling device. Acta Obstet Gynecol Scand 2007, 86:16-21.
5. Andrae B., Andersson T.M., Lambert P.C., Kemetli L., Silfverdal L., Strander B., et al. Screening and cervical cancer cure: population based cohort study. Br Med J 2012, 344:e900.
6. Albrow R., Kitchener H., Gupta N., Desai M. Cervical screening in England: the past, present, and future. Cancer Cytopathol 2012, 120:87-96.
7. Froberg M., Johansson B., Hjerpe A., Andersson S. Human papillomavirus 'reflex' testing as a screening method in cases of minor cytological abnormalities. Br J Cancer 2008, 99:563-568.
8. Sarode V.R., Werner C., Gander R., Foster B., Fulmer A., Saboorian M.H., et al. Reflex human papillomavirus DNA testing on residual liquid-based (TPPT) cervical samples: focus on age-stratified clinical performance. Cancer 2003, 99:149-155.
9. Piana L., Leandri F.X., Le Retraite L., Heid P., Tamalet C., Sancho-Garnier H. HPV-Hr detection by home self sampling in women not compliant with pap test for cervical cancer screening. Results of a pilot programme in Bouches-du-Rhone. Bull Cancer 2011, 98:723-731.
10. Sellors J.W., Lorincz A.T., Mahony J.B., Mielzynska I., Lytwyn A., Roth P., et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. Can Med Assoc J 2000, 163:513-518.
11. Wright T.C., Denny L., Kuhn L., Pollack A., Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. J Am Med Assoc 2000, 283:81-86.
12. Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Jaspars L.H., Voorhorst F.J., et al. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol 2002, 55:435-439.
13. Szarewski A., Cadman L., Mallett S., Austin J., Londesborough P., Waller J., et al. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J Med Screen 2007, 14:34-42.
14. Ronco G., Segnan N. HPV testing for primary cervical cancer screening. Lancet 2007, 370:1740-1742.
15. Bosch F.X., de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003, 31:3-13.
16. Burchell A.N., Richardson H., Mahmud S.M., Trottier H., Tellier P.P., Hanley J., et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol 2006, 163:534-543.
17. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357:1579-1588.
18. Naucler P., Ryd W., Törnberg S., Strand A., Wadell G., Elfgren K., et al. Human papillomavirus and papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357:1589-1597.
19. Naucler P., Ryd W., Törnberg S., Strand A., Wadell G., Hansson B.G., et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007, 97:129-132.
20. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772.
21. Bulkmans N.W., Berkhof J., Bulk S., Bleeker M.C., van Kemenade F.J., Rozendaal L., et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007, 96:1419-1424.
22. Arora R., Kumar A., Prusty B.K., Kailash U., Batra S., Das B.C. Prevalence of high-risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with cytologically negative Pap smear. Eur J Obstet Gynecol Reprod Biol 2005, 121:104-109.
23. Gyllensten U., Sanner K., Gustavsson I., Lindell M., Wikstrom I., Wilander E. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer. Br J Cancer 2011, 105:694-697.
24. Arbyn M., Anttila A., Jordan J., Ronco G., Schenck U., Segnan N., et al. European guidelines for quality assurance in cervical cancer screening. Second edition - summary document. Ann Oncol 2010, 21:448-458.
25. Oscarsson M.G., Wijma B.E., Benzein E.G. Nonattendance in a cervical cancer screening program - what happens if women's requirements are met?. Health Care Women Int 2008, 29:183-197.
26. Oscarsson M.G., Benzein E.G., Wijma B.E., Carlsson P.G. Promotion of cervical screening among nonattendees: a partial cost-effectiveness analysis. Eur J Cancer Prev 2007, 16:559-563.
27. Gök M., Heideman D.A., van Kemenade F.J., Berkhof J., Rozendaal L., Spruyt J.W., et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. Br Med J 2010, 340:c1040.
28. Sanner K., Wikstrom I., Strand A., Lindell M., Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer 2009, 101:871-874.
29. Deleré Y., Schuster M., Vartazarowa E., Hänsel T., Hagemann I., Borchardt S., et al. Cervico-vaginal self-sampling is a reliable method to determine the prevalence of human papillomavirus genotypes in women aged 20 to 30 years. J Clin Microbiol 2011, 49:3519-3522.
30. Wikstrom I., Stenvall H., Wilander E. Attitudes to self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening. Acta Obstet Gynecol Scand 2007, 86:720-725.
31. Darlin L., Borgfeldt C., Forslund O., Henic E., Dillner J., Kannisto P. Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity. J Clin Virol 2013, 56:52-56.
32. Stenvall H., Wikstrom I., Wilander E. High prevalence of oncogenic human papilloma virus in women not attending organized cytological screening. Acta Derm Venereol 2007, 87:243-245.
33. Snijders P.J., Verhoef V.M., Arbyn M., Ogilvie G., Minozzi S., Banzi R., et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2013, 132:2223-2236.
34. Eaker S., Adami H.O., Sparen P. Reasons women do not attend screening for cervical cancer: a population-based study in Sweden. Prev Med 2001, 32:482-491.
35. Szarewski A., Cadman L., Mesher D., Austin J., Ashdown-Barr L., Edwards R., et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. Br J Cancer 2011, 104:915-920.
36. Szarewski A., Poppe W.A., Skinner S.R., Wheeler C.M., Paavonen J., Naud P., et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012, 131:106-116.
37. Oscarsson M.G., Benzein E.G., Wijma B.E. Reasons for non-attendance at cervical screening as reported by non-attendees in Sweden. J Psychosom Obstet Gynaecol 2008, 29:23-31.
38. Knops-Dullens T., de Vries N., de Vries H. Reasons for non-attendance in cervical cancer screening programmes: an application of the integrated model for behavioural change. Eur J Cancer Prev 2007, 16:436-445.
39. Virtanen A., Nieminen P., Luostarinen T., Anttila A. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 2011, 20:1960-1969.